Optiver Holding
CRNX

Optiver Holding’s Crinetics Pharmaceuticals CRNX Stock Holding History

Optiver Holding’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.3K Buy
543
+430
+381% +$16K ﹤0.01% 1514
2026
Q1 		$4.1K Sell
113
-53
-32% -$2.37K ﹤0.01% 1509
2025
Q4 		$7.73K Sell
166
-100
-38% -$4.45K ﹤0.01% 1203
2025
Q3 		$11.1K Sell
266
-102
-28% -$3.26K ﹤0.01% 1229
2025
Q2 		$10.6K Buy
368
+191
+108% +$5.9K ﹤0.01% 987
2025
Q1 		$5.94K Buy
+177
New +$6.61K ﹤0.01% 1050

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Optiver Holding's CRNX Position: Q2 2026 in Review

Optiver Holding increased its Crinetics Pharmaceuticals (CRNX) stake by 381% in Q2 2026, buying an estimated $16K and bringing the position to 543 shares worth $20.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1514.

Optiver Holding first reported a position in CRNX in Q1 2025 and has held it in 6 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Optiver Holding held 543 shares of Crinetics Pharmaceuticals worth $20.3K as of Q2 2026.
  • Optiver Holding bought 430 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $16K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #1514 holding.
  • Optiver Holding first reported a position in Crinetics Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.